Progressive Pulmonary Fibrosis Market Size in the 7MM was USD 1,300 Million in 2023, estimated DelveInsight

DelveInsight’s “Progressive pulmonary fibrosis Market Insights, Epidemiology, and Market Forecast – 2034” report deliver an in-depth understanding of the Progressive pulmonary fibrosis (PPF), historical and forecasted epidemiology as well as the Progressive pulmonary fibrosis (PPF) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Discover Key Insights into the Progressive Pulmonary Fibrosis Market with DelveInsight’s In-Depth Report @ Progressive Pulmonary Fibrosis Market Size

Key Takeaways from the Progressive Pulmonary Fibrosis Market Report

• In November 2024:- Bristol-Myers Squibb-A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
• In November 2024:- Boehringer Ingelheim- A Phase IIa/IIb, Randomised, Double Blind, Placebo-controlled, Parallel-group Dose-finding Study to Examine the Efficacy and Safety of BI 1839100 Administered Orally Over a 12-week Treatment Period in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis With Clinically Meaningful Cough.
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in the 7MM were 135 thousand in 2023.
• The highest total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) were accounted by the US in 2023 (77 thousand), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of PPF with ~11 thousand cases, followed by the United Kingdom, which had prevalent population of 10 thousand in 2023. On the other hand, Spain had the lowest prevalent population (around 6 thousand cases).
• Japan had 10 thousand total diagnosed prevalent cases of Progressive pulmonary fibrosis (PPF) in 2023, accounting for approximately 8% in 7MM.
• The leading Progressive Pulmonary Fibrosis Companies such as Boehringer Ingelheim, Bristol-Myers Squibb, and others
• Promising Progressive Pulmonary Fibrosis Therapies such as BMS-986278, AP01, BI 1839100, BI 1015550, ENV-101, and others.

Stay ahead in the Progressive Pulmonary Fibrosis Therapeutics Market with DelveInsight’s Strategic Report @ Progressive Pulmonary Fibrosis Market Outlook

Progressive Pulmonary Fibrosis Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Interstitial Lung Disease
• Total Diagnosed Prevalent Cases of Interstitial Lung Disease
• Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease
• Total Diagnosed Prevalent Cases of Progressive pulmonary fibrosis

Download the report to understand which factors are driving Progressive Pulmonary Fibrosis epidemiology trends @ Progressive Pulmonary Fibrosis Prevalence

Progressive pulmonary fibrosis Emerging Drugs

• Nerandomilast (BI 1015550): Boehringer Ingelheim

BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects being developed by Boehringer Ingelheim. It has the potential to address both pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function – and inflammation associated with Progressive pulmonary fibrosis (PPF) (ILDs). BI 1015550 represents the first molecule in the class of PDE4B inhibitors that is being studied for IPF and other progressive fibrosing ILDs.

Progressive pulmonary fibrosis Market Outlook

Progressive pulmonary fibrosis (PPF) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PPFs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PPFs. These unmet treatment gaps accentuates the launch of emerging therapies.

Get In-Depth Knowledge on Progressive Pulmonary Fibrosis Market Trends and Forecasts with DelveInsight @ Progressive Pulmonary Fibrosis Treatment Market

Scope of the Progressive Pulmonary Fibrosis Market Report

• Coverage- 7MM
• Pulmonary Fibrosis Companies- Boehringer Ingelheim, Bristol-Myers Squibb, and others
• Progressive Pulmonary Fibrosis Therapies- BMS-986278, AP01, BI 1839100, BI 1015550, ENV-101, and others.
• Progressive Pulmonary Fibrosis Therapeutic Assessment: Progressive Pulmonary Fibrosis Current marketed and Lipodystrophy Emerging Therapies
• Progressive Pulmonary Fibrosis Market Dynamics: Progressive Pulmonary Fibrosis Market drivers and Lipodystrophy Market Barriers

Unlock Strategic Insights with DelveInsight’s Comprehensive Progressive Pulmonary Fibrosis Market Report @ Progressive Pulmonary Fibrosis Market Drivers and Barriers

Table of Content

1 Key Insights

2 Report Introduction

3 Progressive pulmonary fibrosis (PPF) Market Overview at a Glance

4 Methodology of Progressive pulmonary fibrosis (PPF) Epidemiology and Market

5 Executive Summary of Progressive pulmonary fibrosis (PPF)

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Therapies

12 Progressive pulmonary fibrosis (PPF): Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity